 |
| Site Index |
|
|
|
||||
About UsTbilisiPhage ResearchPhage TherapyPhageBiotics Funds
|
Companies |
|||
|
Tbilisi phage producers Tbilisi Phage ProducersThe Eliava Institute Since privatization of the industrial part, the hospitals and clinics in Georgia generally still get the therapeutic phages on which they depend from the laboratory of Zemphira Alavidze and Amiran Meipariani at the Eliava Institute and work closely with them to get phages that work well for their patients. Two other labs have started making and selling some medical and veterinary products as well. Contact: zemal@caucasus.net; tato_gabisonia@yahoo.co.uk Bacterial identification and phage and antibiotic susceptibility testing are carried out through a small company, Diagnostic, based within the Institute itself and running the small clinic on its grounds. Many people from various Institute labs supplement their minimal Academy salaries of $30-60 monthly with some income from carrying out the testing and the phage production here. Licensing and quality control are under the auspices of the Institute. The several labs involved in phage production have now established a non-profit Eliava Phage Production Renaissance Foundation to refurbish the space and set up a central local- and research-scale production facility, as described in some detail elsewhere here. Biopharm Pharmaceuticals Lado Gulisashvili and Lela Kalandarishvili - biopharm@got.ge. Biopharm obtained most of original big main production plant of the Eliava Institute after privatization, and has enhanced its capacity with much good equipment obtained from bankrupt companies, including in Moscow. They make vitamins, various biomedical reagents, probiotics, and currently also about 20 liters a month of phage products, including pills. They use primarily the phages that were being produced before privatization, with some research focussed on methods of delivery that can be patented, such as new capsule formulations. (The basic commercial phage mixtures require production licenses but are not patentable, having been in use since the time of d'Herelle and also reported in many ways in the literature.) Using a phage-oriented subsidiary, Advanced Biophage Technology, Leila is working to build partnerships beyond Georgia. Biochimpharm Alexandr Golejashvili ("Aleko") - Biochimpharm owns the large privatized production facility for phage tablets and some other products in the main building. The company was only formed in 2000 and is licensed to produce dysentary tablets and several other products, but has been able to make only limited use to date of the large facilities. The area is in relatively good shape physically, with large if old fermenters and excellent filtration devices and machines that could make 100,000 tablets per hour. They have just been awarded an ISTC grant in combination with the Eliava Institute's Liana Gachechiladze to focus on Serratia as well as Pseudomonas. They are negotiating the final work plan and beginning some refurbishing. US, Canadian, and Mexican CompaniesExponential Biotherapies, Inc. Richard Carlton, M.D. 150 Main Street, Port Washington, NY 11050 phone: (516) 883-6883 fax: (516) 883-6903 e-mail: carltonebi@erols.com business: Therapeutic use of phages in humans, food production animals and companion animals. Dr. Richard Carlton, who in 1993 formed Exponential Biotherapies - Founded in 1993, Exponential was the first American company devoted exclusively to phage therapy work, initially in the NIH labs of Carl Merrill and Sankar Adhya under a CRADA agreement, leading to several patents and a very interesting PNAS paper on the selection for long-circulating bacteriophages for therapeutic purposes. In 1997, Exponential rented its own lab space in Rockvillle, MD and now employs 12 people. They focussed initially on vancomycin-resistant enterococcus (VRE), and have successfully completed Phase 1 clinical trials. They have also been exploring several other interesting phage therapy applications, including phage preparations for additional pathogens, and phage preparations to control bacterial contamination in the food industry in Europe and the US. J. Ramachandran, 3279 Emerson, Palo Alto, CA 94306. Phone: 650-856 9118 Fax: 650-856 9642 jram@gangagen.com; Gangagen Life Sciences Inc: Dr. Kishore Murthy, Chief Scientific Officer, 1740, Woodroffe Ave, Building 400, Suite # 2, Ottawa, Ontario, K2G3R8, kmurthy@gangagen.com; Gangagen Biotechnologies Ltd: Dr. Goda Krishna, #5 AC, 705 II Block, Hennur Road, Banaswadi Layout, Bangalore 560043 Phone: +91-80-5448138/5448146 Fax: 91-80-5447996; godakrishna@gangagen.com business: GangaGen is interested both the developed and the developing nations market. It emphasizes the diagnosis, treatment and prevention of nosocomial (hospital-acquired) infections, secondary infections (e.g. following surgery), and topical infections (e.g. burns and wounds) and plans to develop phage therapies to treat enteric infections as well as upper respiratory tract infections caused by bacterial pathogens. In addition, GangaGen is developing phages for the control and elimination of bacterial pathogens in animals, plants and the environment. Torrey Brown address: The Warehouse at Camden Yards, 323 W. Camden Street, Suite 675, Baltimore, Maryland 21201 phone: (410) 659-7330 fax: (410) 625-2323 e-mail: info@Intralytix.com web site: www.Intraltyix.com business: Intralytix, Inc. is a development stage biotechnology company focused on the production and marketing of products using bacteriophages to control bacterial pathogens in environmental, food processing, and medical settings. Phage Therapeutics International Inc. (PhageTx) Richard Honour address: 22116 23rd Drive SE, Bothell, Washington 98021 web site: phone: 425-482-9511 fax: 425-482-0834 e-mail: info@phagetx.com business: formed to develop, manufacture and achieve regulatory approval of bacteriophage pharmaceutical products for the treatment of antibiotic-resistant and other bacterial infections Rosemonde Mandeville address: Montreal, Canada phone: (514) 496-1488 fax: (514) 496-1521 e-mail: email@biophage.com web site: www.biophage.com business: Biophage is licensed to exploit new innovative and patented platform technologies in the health industry with focus on cancer, infection/inflammation and immune modulation. Europe and IsraelAsher Wilf; address: 4, Pekeris St., Rabin Science Park, Rehovot 76702, Israel. phone: cell: +972-52-446782; Tel:972-8-947-1837 fax: +972 8-947-1845; e-mail: asher@phage-biotech.com or info@phage-biotech.com or web site: ; business: Research, development, standardization, production, and application of lytic bacteriophage technology toward an array of clinical, veterinary, agricultural, industrial, and ecologic applications. They are presently conducting 2nd round of animal pre-clinical experiments of Pseudomonas Keratitis and Endophthalmitis phage treatments with excellent preliminary results; a patent is pending. address: HEXAL Gentech ForschungsGmbH, Industriestr. 25, 83607, Holzkirchen, Germany e-mail: info@greinerbioone.com web site: business: new directions include exploring use of a novel, bacteriophage-based therapeutic for treatment of multidrug resistance bacterial infections. Their approach is based on use of bacteriophage (naturally occurring bacterial viruses which are noninfectious to humans) that are engineered to package specifically designed plasmids that kill bacteria (LADS, lethal agent delivery system) and has been developed in collaboration with Laura Kasman's group in South Carolina. DD Pharma Nodar A. Danelia, M.D. e-mail: danelia@bacteriophage.net business: Phage therapy, using phages from Georgia. MicroPeace Biotechnology Consulting contact: Dr. Ipek Kurtboke, LPO Box 2093, Hawthorn, Melbourne, Victoria 3122, Australia phone: +61 (03) 9813 5660 fax: +61 (03) 9813 5660 e-mail: micropeace@hotmail.com web site: business: Developing new compounds for future use against drug-resistant bacteria and/or for chemical modifications for field applications by screening for new metabolites and evaluating the potential of less known or new bacteria taxa.. Bacteriophage are being used as natural indicators of the presence of rare taxa in a selected test substrate, to determine the relatedness of the isolated taxa and to deselect unwanted taxa on isolation plates in the process of target specific selective isolations. Micropeace provides consultancy to biotechnology companies and research institutes interested in detection of rare or novel actinomycetes and other bacteria on ways to use phages as effective tools in this search. |
Bacteriophage |
|||
|
Last Updated: May 29, 2008 All content and images on this site are copyrighted by The Evergreen State College. |
||||
